Danil V Makarov

Summary

Affiliation: Johns Hopkins University
Country: USA

Publications

  1. ncbi request reprint The discovery of prostate specific antigen as a biomarker for the early detection of adenocarcinoma of the prostate
    Danil V Makarov
    James Buchanan Brady Urological Institute, The Johns Hopkins Medical Institutions, 600 North Wolfe Street, Baltimore, MD 21287, USA
    J Urol 176:2383-5. 2006
  2. pmc Updated nomogram to predict pathologic stage of prostate cancer given prostate-specific antigen level, clinical stage, and biopsy Gleason score (Partin tables) based on cases from 2000 to 2005
    Danil V Makarov
    Department of Urology, The James Buchanan Brady Urological Institute, The Johns Hopkins Medical Institutions, Baltimore, Maryland 21287 2101, USA
    Urology 69:1095-101. 2007
  3. pmc Using nuclear morphometry to predict the need for treatment among men with low grade, low stage prostate cancer enrolled in a program of expectant management with curative intent
    Danil V Makarov
    Department of Urology, The James Buchanan Brady Urological Institute, The Johns Hopkins Medical Institutions, Baltimore, Maryland 21287, USA
    Prostate 68:183-9. 2008
  4. ncbi request reprint The natural history of men treated with deferred androgen deprivation therapy in whom metastatic prostate cancer developed following radical prostatectomy
    Danil V Makarov
    James Buchanan Brady Urological Institute and the Sidney Kimmel Comprehensive Cancer Center, The Johns Hopkins Medical Institutions, Baltimore, Maryland 21287, USA
    J Urol 179:156-61; discussion 161-2. 2008
  5. doi request reprint Biomarkers for prostate cancer
    Danil V Makarov
    The James Buchanan Brady Urological Institute, The Johns Hopkins Medical Institutions, Baltimore, Maryland, USA
    Annu Rev Med 60:139-51. 2009
  6. ncbi request reprint Pathological outcomes and biochemical progression in men with T1c prostate cancer undergoing radical prostatectomy with prostate specific antigen 2.6 to 4.0 vs 4.1 to 6.0 ng/ml
    Danil V Makarov
    James Buchanan Brady Urological Institute, and the Department of Urology, The Johns Hopkins Medical Institutions, Baltimore, Maryland 21287, USA
    J Urol 176:554-8. 2006
  7. doi request reprint Prediction of prostate-specific antigen recurrence in men with long-term follow-up postprostatectomy using quantitative nuclear morphometry
    Robert W Veltri
    James Buchanan Brady Urological Institute, The Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA
    Cancer Epidemiol Biomarkers Prev 17:102-10. 2008
  8. doi request reprint DNA content in the diagnostic biopsy for benign-adjacent and cancer-tissue areas predicts the need for treatment in men with T1c prostate cancer undergoing surveillance in an expectant management programme
    Sumit Isharwal
    The James Buchanan Brady Urological Institute, The Johns Hopkins University School of Medicine, Baltimore, MD, USA
    BJU Int 105:329-33. 2010
  9. pmc p300 (histone acetyltransferase) biomarker predicts prostate cancer biochemical recurrence and correlates with changes in epithelia nuclear size and shape
    Sumit Isharwal
    James Buchanan Brady Urological Institute, Johns Hopkins University School of Medicine, Baltimore, Maryland 21287, USA
    Prostate 68:1097-104. 2008
  10. doi request reprint Prostate specific antigen at the initial diagnosis of metastasis to bone in patients after radical prostatectomy
    Stacy Loeb
    Brady Urological Institute, Johns Hopkins Medical Institutions, Baltimore, Maryland, USA
    J Urol 184:157-61. 2010

Detail Information

Publications21

  1. ncbi request reprint The discovery of prostate specific antigen as a biomarker for the early detection of adenocarcinoma of the prostate
    Danil V Makarov
    James Buchanan Brady Urological Institute, The Johns Hopkins Medical Institutions, 600 North Wolfe Street, Baltimore, MD 21287, USA
    J Urol 176:2383-5. 2006
    ..We review the history of the discovery of prostate specific antigen as a biomarker for the early detection of adenocarcinoma of the prostate...
  2. pmc Updated nomogram to predict pathologic stage of prostate cancer given prostate-specific antigen level, clinical stage, and biopsy Gleason score (Partin tables) based on cases from 2000 to 2005
    Danil V Makarov
    Department of Urology, The James Buchanan Brady Urological Institute, The Johns Hopkins Medical Institutions, Baltimore, Maryland 21287 2101, USA
    Urology 69:1095-101. 2007
    ..To update the 2001 "Partin tables" with a contemporary patient cohort and revised variable categorization, correcting for the effects of stage migration...
  3. pmc Using nuclear morphometry to predict the need for treatment among men with low grade, low stage prostate cancer enrolled in a program of expectant management with curative intent
    Danil V Makarov
    Department of Urology, The James Buchanan Brady Urological Institute, The Johns Hopkins Medical Institutions, Baltimore, Maryland 21287, USA
    Prostate 68:183-9. 2008
    ..We assessed the use of quantitative clinical and pathologic information to predict which patients would eventually require treatment for prostate cancer (CaP) in an expectant management (EM) cohort...
  4. ncbi request reprint The natural history of men treated with deferred androgen deprivation therapy in whom metastatic prostate cancer developed following radical prostatectomy
    Danil V Makarov
    James Buchanan Brady Urological Institute and the Sidney Kimmel Comprehensive Cancer Center, The Johns Hopkins Medical Institutions, Baltimore, Maryland 21287, USA
    J Urol 179:156-61; discussion 161-2. 2008
    ....
  5. doi request reprint Biomarkers for prostate cancer
    Danil V Makarov
    The James Buchanan Brady Urological Institute, The Johns Hopkins Medical Institutions, Baltimore, Maryland, USA
    Annu Rev Med 60:139-51. 2009
    ..Future research should focus on validation of already existing biomarkers and the discovery of new markers to identify men with aggressive prostate cancer...
  6. ncbi request reprint Pathological outcomes and biochemical progression in men with T1c prostate cancer undergoing radical prostatectomy with prostate specific antigen 2.6 to 4.0 vs 4.1 to 6.0 ng/ml
    Danil V Makarov
    James Buchanan Brady Urological Institute, and the Department of Urology, The Johns Hopkins Medical Institutions, Baltimore, Maryland 21287, USA
    J Urol 176:554-8. 2006
    ..5 ng/ml as opposed to the more traditional greater than 4.0 ng/ml. We compared outcomes between men with clinical stage T1c disease undergoing radical prostatectomy who had a low vs slightly increased prostate specific antigen...
  7. doi request reprint Prediction of prostate-specific antigen recurrence in men with long-term follow-up postprostatectomy using quantitative nuclear morphometry
    Robert W Veltri
    James Buchanan Brady Urological Institute, The Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA
    Cancer Epidemiol Biomarkers Prev 17:102-10. 2008
    ....
  8. doi request reprint DNA content in the diagnostic biopsy for benign-adjacent and cancer-tissue areas predicts the need for treatment in men with T1c prostate cancer undergoing surveillance in an expectant management programme
    Sumit Isharwal
    The James Buchanan Brady Urological Institute, The Johns Hopkins University School of Medicine, Baltimore, MD, USA
    BJU Int 105:329-33. 2010
    ..Study Type - Prognosis (case series)Level of Evidence 4...
  9. pmc p300 (histone acetyltransferase) biomarker predicts prostate cancer biochemical recurrence and correlates with changes in epithelia nuclear size and shape
    Sumit Isharwal
    James Buchanan Brady Urological Institute, Johns Hopkins University School of Medicine, Baltimore, Maryland 21287, USA
    Prostate 68:1097-104. 2008
    ..Therefore, we evaluated the prognostic value of p300 expression and its correlation with nuclear alterations seen in tumor cells in men with long-term follow-up after radical prostatectomy (RP)...
  10. doi request reprint Prostate specific antigen at the initial diagnosis of metastasis to bone in patients after radical prostatectomy
    Stacy Loeb
    Brady Urological Institute, Johns Hopkins Medical Institutions, Baltimore, Maryland, USA
    J Urol 184:157-61. 2010
    ..This information would be useful in determining when to initiate androgen deprivation therapy...
  11. doi request reprint ProPSA and diagnostic biopsy tissue DNA content combination improves accuracy to predict need for prostate cancer treatment among men enrolled in an active surveillance program
    Sumit Isharwal
    James Buchanan Brady Urological Institute, Johns Hopkins University School of Medicine, Baltimore, Maryland 21287, USA
    Urology 77:763.e1-6. 2011
    ....
  12. pmc Does laterality of positive needle biopsy in clinical T2a patients with prostate cancer affect biochemical recurrence-free survival?
    Ina Wu
    James Buchanan Brady Urological Institute, Department of Urology, Johns Hopkins Hospital, Baltimore, Maryland, USA
    Urology 72:1219-23. 2008
    ..To test whether patients with clinical Stage T2a prostate cancer with biopsy-proven disease only contralateral to the palpable abnormality experience outcomes similar to those of patients with clinical Stage T1c...
  13. doi request reprint Is it possible to compare PSA recurrence-free survival after surgery and radiotherapy using revised ASTRO criterion--"nadir + 2"?
    Matthew E Nielsen
    James Buchanan Brady Urological Institute, Johns Hopkins University School of Medicine, Baltimore, Maryland 21287 2101, USA
    Urology 72:389-93; discussion 394-5. 2008
    ..Because this definition inevitably will be used to compare cancer control rates after radiotherapy to those after surgery, this study examined the effect of this comparison...
  14. ncbi request reprint Gleason score 7 prostate cancer on needle biopsy: is the prognostic difference in Gleason scores 4 + 3 and 3 + 4 independent of the number of involved cores?
    Danil V Makarov
    Department of Pathology, The James Buchanan Brady Urological Institute, The Johns Hopkins Medical Institutions, Baltimore, Maryland, USA
    J Urol 167:2440-2. 2002
    ..This practice would remove a source of poor interobserver reproducibility when grading prostate cancer on needle biopsy...
  15. ncbi request reprint Effect of testosterone replacement therapy on prostate tissue in men with late-onset hypogonadism: a randomized controlled trial
    Leonard S Marks
    Department of Urology, Geffen School of Medicine, University of California, Los Angeles, USA
    JAMA 296:2351-61. 2006
    ..Prostate safety is a primary concern when aging men receive testosterone replacement therapy (TRT), but little information is available regarding the effects of TRT on prostate tissue in men...
  16. pmc Long-term satisfaction and predictors of use of intracorporeal injections for post-prostatectomy erectile dysfunction
    Vinay Prabhu
    Department of Urology, New York University School of Medicine, New York, New York 10016, USA
    J Urol 189:238-42. 2013
    ..We examined factors associated with intracorporeal injection use, long-term satisfaction with intracorporeal injection and reasons for discontinuation in men treated with radical prostatectomy...
  17. ncbi request reprint Nucleic acid-based marker approaches to urologic cancers
    Robert W Veltri
    Department of Urology, The Brady Urologic Institute, Johns Hopkins University School of Medicine, Baltimore, MD 21287 2101, USA
    Urol Oncol 24:510-27. 2006
    ..We review only nucleic acid-based molecular biomarkers in urologic oncology that can assist the clinician in establishing the diagnosis of disease, or that can predict the behavior of the disease or the patient's survival...
  18. doi request reprint Surgical decompression is associated with decreased mortality in patients with sepsis and ureteral calculi
    Michael S Borofsky
    Department of Urology, Nephrology Division and Section on Value and Effectiveness, New York University Langone Medical Center, New York University, New York, New York 10016, USA
    J Urol 189:946-51. 2013
    ..We determined whether a mortality benefit is associated with this intervention...
  19. doi request reprint The effect of ureteral stent placement on post-ureteroscopy complications: a meta-analysis
    Danil V Makarov
    James Buchanan Brady Urological Institute, The Johns Hopkins University School of Medicine, Baltimore, Maryland 21209, USA
    Urology 71:796-800. 2008
    ..To determine, by systematic review and meta-analysis of all randomized controlled trials examining ureteral stent placement after ureteroscopy, whether the presence or absence of a stent was associated with postoperative complications...
  20. doi request reprint Patient centered outcomes in prostate cancer treatment: predictors of satisfaction up to 2 years after open radical retropubic prostatectomy
    Nitya E Abraham
    Department of Urology, New York University School of Medicine, New York, New York, USA
    J Urol 184:1977-81. 2010
    ..Few groups have examined satisfaction after prostate cancer treatment. We determined 1) predictors of satisfaction between 3 months and 2 years after open radical retropubic prostatectomy, and 2) whether these factors are time dependent...
  21. ncbi request reprint Comparison of WHO/ISUP and WHO classification of noninvasive papillary urothelial neoplasms for risk of progression
    Hemamali Samaratunga
    Department of Pathology, Royal Brisbane Hospital, Brisbane, Australia
    Urology 60:315-9. 2002
    ..To investigate the relation of the World Health Organization/International Society of Urological Pathology (WHO/ISUP) system for bladder neoplasia to prognosis...